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weekly cost exceeded $50 were more likely to discontinue than
patients with lower costs (HR 1.59, P < 0.001). CONCLUSION:
The majority of patients have very reasonable OOP for biolog-
ics. However, a small number of patients are burdened with high
OOP costs. The adverse impact of high OOP on adherence and
persistence needs to be considered when making decisions about
increasing co-pays.
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OBJECTIVES: Rheumatoid Arthritis (RA) imposes a signiﬁcant
burden of disease to both affected patients and the society as a
whole. We performed the ﬁrst German claims database analysis
among members of a statutory health insurance fund to estimate
RA treatment prevalence, to describe prescription patterns and
assess overall disease burden. METHODS: We based our analy-
sis on billing data from the years 2000 to 2004 of a German
sickness fund covering 1.5 million beneﬁciaries. RA patients
were identiﬁed by either inpatient or sick leave records due to
ICD-10 codes (M05, M06) or at least two prescriptions of a
disease-modifying drug (DMARD) or a TNF-α inhibitor. We
excluded patients with a variety of co-medications and diag-
noses, e.g. Psoriasis, Crohn’s Disease and malignant disease. We
speciﬁed treatment prevalence and patterns of RA disease man-
agement with DMARDs and TNFs in the selected population.
RESULTS: Out of the 728,111 beneﬁciaries continuously
enrolled between 2000 and 2004 n = 5850 (mean age: 43 ± 14
years) fulﬁlled the inclusion criteria for RA. RA treatment preva-
lence, standardized to the general German population was
0.68% for men and 1.25% for women. 43% of the patients with
RA were treated with DMARDs and 3.2% received TNF-α
inhibitors. 26% of RA-patients were initiated on DMARD
therapy by a general practitioner. Compared to the RA popula-
tion as a whole patients receiving TNF-α inhibitors were char-
acterized by a 2.6 fold number of sick leaves and a 6.4 fold
number of hospitalizations in the year prior to therapy initiation.
CONCLUSION: The RA treatment prevalence found in this
study is in line with local epidemiological research. As less than
half of RA-patients had a prescription of a DMARD, this may
indicate that therapeutic standards are not met. TNF-α inhibitors
are mainly prescribed in a high burden RA subpopulation.
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OBJECTIVES: The purpose of this study was to evaluate the
impact of specialty pharmacy prior authorization (SPA) program
on prescription costs for the biologic response modiﬁers
(Amevive, Enbrel, Humira, Kineret, Raptiva, and Remicade)—a
new class of medication for the treatment of several disease states
such as Rheumatoid Arthritis. METHODS: Prescription data
were obtained from a pharmacy beneﬁt manager’s pharmacy
claims database. This study used a retrospective case-control
one-to-one matching approach based on patient age, gender, and
client characteristics including the number of eligible members,
client type and region. The case clients had enrolled in the SPA
program in January 2005 and had remained part of the program
by December 31, 2005. Clients whose members did not use the
biologic response modiﬁers were excluded from the study. Per
eligible member per month (PMPM) total costs was the outcome
measured. RESULTS: The average PMPM total, plan and
member costs were $1.33, $1.30, and $0.03 in the case group,
while the average PMPM total, plan and member costs were
$1.51, $1.47 and $0.04 in the control group. Clients who imple-
mented a specialty pharmacy prior authorization program for
the biologic response modiﬁers saved an estimated PMPM total
cost of $0.18. CONCLUSION: Implementing a specialty phar-
macy prior authorization program reduced prescription drug
costs for the biologic response modiﬁers.
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OBJECTIVES: A major component of the economic burden
associated with the treatment of arthritis relates to surgical joint
replacement of the hips or knees. The objective of this study is
to compare the burden of hip/knee replacements performed in
the U.S. in the year 2000 and 2004. METHODS: The Health
care Cost and Utilization Project—National Inpatient Survey”
(HCUP-NIS) was analyzed to estimate the changes in the burden
of hip and knee replacements in the U.S. The HCUP itself is a
compilation of billing data which can yield estimates of national
hospital charges as well as the total number of hip and knee
replacement procedures. In 2004, the HCUP-NIS database con-
tained nearly 8 million records from about 1000 hospitals. The
ICD-9-CM procedure codes used in identifying patients are
81.51 (total hip replacement) and 81.54 (Total/partial knee
replacement). RESULTS: In the year 2004, approximately
225,900 total hip replacement and 431,458 total knee replace-
ment procedures were performed in the U.S. This is a 37%
increase in hip replacement procedures and a 53% increase in
total knee replacements compared to the year 2000 (164,458
total hip replacement and 281,534 total knee replacement). In
terms of economic burden, the national bill of hospital charges
increased by 111% (from $10.8 billion in year 2000 to $22.9
billion in year 2004). CONCLUSION: The data shows a steep
increase in the burden of joint replacements. Not considering pre
and post-operation care, the estimated hospital charges for joint
replacements alone were nearly 22.9 billion dollars in the United
States during the year 2004. This data, however, does not
provide reasons of steep increase in the burden of joint replace-
ments during this four year period. Further study is needed to
address these issues.
ARTHRITIS—Methods & Concepts
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OBJECTIVES: The introduction of tumor necrosis factor (TNF)
inhibitors such as etanercept and inﬂiximab has represented a
critical advance in the available treatments for patients with
Ankylosing Spondylitis (AS). Several clinical studies have shown
superior efﬁcacy of TNF inhibitors, but high costs and infrequent
instances of serious adverse side effects ask for priority setting.
The aim of this review was to identify and summarize the phar-
